Mga Tweet

	Gilead Sciences @GileadSciences	16 na oras
	Sumasagot kay @Jules_Clarke Thank you @Jules_Clarke for your question. Please send us a DM or email us at [email protected] and we’d be happy to provide the latest updates.
	Tingnan ang pag-uusap ·

	Gilead Sciences @GileadSciences	22 oras
	Congratulations to the awardees of Gilead’s International Research Scholars Program in Liver Disease: @MartinCornillet; Marta Varela-Rey, Ph.D.; and Adriaan Holleboom, M.D., Ph.D. Learn more about the program here: bit.ly/2yq9Ghh. #ILC2019 pic.twitter.com/hCODjzsglU
	Tingnan ang larawan ·

	Gilead Sciences @GileadSciences	Abr 13
	Peer support and better access to care and treatment are critical to achieving #HCV elimination in the drug user community. Listen to Sergio’s story to find out how he is breaking down barriers to care. #ILC2019 pic.twitter.com/VsFWrzkyVb
	Tingnan ang larawan ·

	Gilead Sciences @GileadSciences	Abr 13
	According to @DrLoomba, data from Canada shows a strong patient preference for #fibroscan to diagnose #NASH compared to liver biopsy. #ILC2019 pic.twitter.com/UARibD1bjC
	Tingnan ang larawan ·

	Gilead Sciences @GileadSciences	Abr 13
	Considerations for #NASH screening, according to Michael Roden: age, #T2DM, insulin resistance, #steatosis, #obesity and abnormal LFTs. #ILC2019 pic.twitter.com/yycG6akcms
	Tingnan ang larawan ·

	Gilead Sciences @GileadSciences	Abr 13
	Live from our #NASH symposium, Laurent Castera states that ~41% of #NASH patients have advanced fibrosis at diagnosis. #ILC2019 pic.twitter.com/1lsBZlx8zH
	Tingnan ang larawan ·

	Gilead Sciences @GileadSciences	Abr 12
	The elimination of #HCV happens one step at a time and, according to Maria Buti, small micro-elimination projects can lead to big changes. #ILC2019 pic.twitter.com/0dVWsNP3kD
	Tingnan ang larawan ·

	Gilead Sciences @GileadSciences	Abr 12
	From our #HCV symposium at #ILC2019: Michael Gschwantler and Stefan Zeuzem discuss the need for collaboration to achieve HCV elimination. pic.twitter.com/VvFgXL3haY
	Tingnan ang larawan ·

	Gilead Sciences @GileadSciences	Abr 12
	Diagnosis of advanced fibrosis due to #NASH currently requires a liver biopsy. We are committed to evaluating the use of noninvasive tests to help identify patients with advanced fibrosis due to NASH, which may reduce the need for invasive biopsies. #ILC2019 pic.twitter.com/nIaPOMOEtj
	Tingnan ang larawan ·

	Gilead Sciences @GileadSciences	Abr 12
	Today at #ILC2019, Chief Patient Officer @GreggAlton will participate in the EASL-EILF seminar and speak about the vital role industry can play in an effective elimination strategy. #HCV #HBV pic.twitter.com/scCB8OmLTi
	Tingnan ang larawan ·

	Gilead Sciences @GileadSciences	Abr 12
	Today, we announced our intent to initiate a #NASH clinical collaboration with Novo Nordisk: bit.ly/2X42Wxx
	Tingnan ang mga detalye ·

	Ni-retweet ni Gilead Sciences
	NatlAcad of Sciences @theNASciences	Abr 11
	Join us in honoring @theNAEng member John C. Martin of @GileadSciences for his contribution to human health. Watch online as he is presented the 2019 NAS Award for Chemistry in Service to Society. #NASaward #service #NAS156 bit.ly/NAS156awards pic.twitter.com/4X5j1F1zdu
	Tingnan ang larawan ·

	Gilead Sciences @GileadSciences	Abr 11
	Today we are pleased to announce new data on the use of our #HCV and #HBV medicines, and progress from our HBV cure research program at #ILC2019: bit.ly/2VzY6rj.
	Tingnan ang mga detalye ·

	Gilead Sciences @GileadSciences	Abr 11
	.@HenryLYChan discusses the future of #HBV and why it’s important to maintain a patient-centric approach to disease management. #ILC2019 pic.twitter.com/ERXMhUGrA0
	Tingnan ang larawan ·

	Gilead Sciences @GileadSciences	Abr 11
	Today at our #HBV symposium, Dr. Kosh Agarwal talks about how the elimination of #HBV as a public health concern starts with prevention. #ILC2019 pic.twitter.com/7VYPXi3iJ7
	Tingnan ang larawan ·

	Gilead Sciences @GileadSciences	Abr 11
	Today we are proud to announce the latest data from our #NASH clinical research program being presented at #ILC2019: bit.ly/2UM192M.
	Tingnan ang mga detalye ·

	Gilead Sciences @GileadSciences	Abr 11
	#NASH is a chronic and progressive liver disease that can lead to fibrosis and impair liver function. Hilary shares her story to challenge misconceptions and help others living with the condition. #ILC2019 pic.twitter.com/rRW4Ahw1bg
	Tingnan ang larawan ·

	Ni-retweet ni Gilead Sciences
	AIDSVu @AIDSVu	Abr 10
	Today is #NYHAAD! This day was created to educate the public about the impact of #HIV/AIDS on youth and highlight the work youth do to fight against it. Check out AIDSVu's new infographics and share with your networks to raise awareness: aidsvu.org/national-youth… pic.twitter.com/8s9EcQ8wfp
	Tingnan ang larawan ·

	Gilead Sciences @GileadSciences	Abr 10
	We look forward to sharing our latest liver disease research this week at #ILC2019 in Vienna. pic.twitter.com/OwyTTFXRG2
	Tingnan ang larawan ·

	Gilead Sciences @GileadSciences	Abr 9
	Fueled by the opioid epidemic, since 2010, hepatitis C infection rates have risen dramatically throughout central Appalachia. Read our new @MorningConsult op-ed with @HarmReduction to learn how we’re addressing this through our #HepConnect initiative: bit.ly/2Vx7lbO.
	Tingnan ang buod ·